



## Clinical trial results:

**A phase II pilot study to assess the presence of molecular factors predictive for hematologic response in myelodysplastic syndrome patients receiving deferasirox therapy in hematological centers in Belgium using gene expressing profiling from baseline bone marrow.**

### Summary

EudraCT number	2015-003775-30
Trial protocol	BE
Global end of trial date	01 July 2016

### Results information

Result version number	v1 (current)
This version publication date	14 October 2017
First version publication date	14 October 2017

### Trial information

#### Trial identification

Sponsor protocol code	CICL670ABE04
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02663752
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharmaceuticals AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Novartis Pharmaceuticals AG, Novartis Pharmaceuticals AG, 41 613241111,
Scientific contact	Novartis Pharmaceuticals AG, Novartis Pharmaceuticals AG, 41 613241111,

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	01 July 2016
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	01 July 2016
Was the trial ended prematurely?	Yes

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To identify differentially expressed genes in baseline bone marrow samples of low and intermediate-1 risk MDS patients with a hematologic response vs non-responder patients based on NGS of the whole transcriptome to search for a predictive gene signature.

---

Protection of trial subjects:

Retrospective design was selected because, by comparison with classical investigational design, it does not require delay in treatment initiation. In addition, this allows the study to be shorter as we do not have to wait for a hematological response to develop in the study population. This specific design is made possible due to the storage and availability of most baseline bone marrow aspirates taken at the time of MDS diagnosis in Belgian hospitals and preserved under the right circumstances to perform RNA sequencing. Patients

---

Background therapy: -

---

Evidence for comparator: -

---

Actual start date of recruitment	30 May 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Belgium: 1
Worldwide total number of subjects	1
EEA total number of subjects	1

---

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	1

---

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Due to low recruitment (1 patient after 12 months of recruitment) the study has been cancelled.

### Pre-assignment

Screening details:

Only 1 patient was recruited.

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Deferasirox
------------------	-------------

Arm description:

All patients are already on commercial deferasirox before entering the study.

Arm type	Deferasirox was prerequisite for trial entry
Investigational medicinal product name	Deferasirox
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

The patient continued taking the same dose as he was used to before study entry and when deferasirox is provided as IMP. There was no treatment administration specific to this study. However, eligibility criteria include the need for patients to be treated with deferasirox.

<b>Number of subjects in period 1</b>	Deferasirox
Started	1
Completed	1

## Baseline characteristics

---

### Reporting groups

Reporting group title	Overall Period
-----------------------	----------------

Reporting group description: -

Reporting group values	Overall Period	Total	
Number of subjects	1	1	
Age categorical			
Units: Subjects			
From 65-84 years	1	1	
Gender categorical			
Units: Subjects			
Female	0	0	
Male	1	1	

## End points

### End points reporting groups

Reporting group title	Deferasirox
Reporting group description: All patients are already on commercial deferasirox before entering the study.	

### Primary: Fold increase/decrease in gene transcription from baseline bone marrow aspirate of responders versus nonresponders'

End point title	Fold increase/decrease in gene transcription from baseline bone marrow aspirate of responders versus nonresponders' <sup>[1]</sup>
-----------------	--

End point description:

Using next-generation sequencing, gene expression profiling in responder and non-responder patients were to be performed on existing bone marrow aspirate samples. Gene transcription were then to be compared between the two groups and the fold increase/decrease in differentially expressed genes were to be calculated.

End point type	Primary
----------------	---------

End point timeframe:

18 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Since the study has been cancelled and only 1 patient has been included, no statistics has been performed.

<b>End point values</b>	Deferasirox			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[2]</sup>			
Units: Number				

Notes:

[2] - Patient was randomized but did not complete trial.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to response

End point title	Time to response
-----------------	------------------

End point description:

The time to response is defined as the time (in months) between the date of deferasirox initiation and the date of the first documented hematological response only in the responder group.

End point type	Secondary
----------------	-----------

End point timeframe:

18 months

<b>End point values</b>	Deferasirox			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[3]</sup>			
Units: Number				

Notes:

[3] - Patient was randomized but did not complete trial.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Changes in serum ferritin levels

End point title	Changes in serum ferritin levels
End point description: From baseline to time of response (responder group) or time to last follow up (non-responders).	
End point type	Secondary
End point timeframe: Baseline, 18 months	

<b>End point values</b>	Deferasirox			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[4]</sup>			
Units: Number				

Notes:

[4] - Patient was randomized but did not complete trial.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Deferasirox dose used

End point title	Deferasirox dose used
End point description: Deferasirox dose is defined as the average daily dose (mg/kg/d) given to the patient from treatment initiation to the emergence of hematological response in the responder group or the time of enrollment in the study in the nonresponder group.	
End point type	Secondary
End point timeframe: 18 months	

<b>End point values</b>	Deferasirox			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[5]</sup>			
Units: Number				

Notes:

[5] - Patient was randomized but did not complete trial.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Changes in serum transferrin levels

End point title	Changes in serum transferrin levels
End point description:	From baseline to time of response (responder group) or time to last follow up (non-responders).
End point type	Secondary
End point timeframe:	Baseline, 18 months

<b>End point values</b>	Deferasirox			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[6]</sup>			
Units: Number				

Notes:

[6] - Patient was randomized but did not complete trial.

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	Deferasirox
-----------------------	-------------

Reporting group description:

All patients are already on commercial deferasirox before entering the study.

Serious adverse events	Deferasirox		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Deferasirox		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The patient did not experience any Adverse Events during the trial.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The trial was terminated due to low enrollment.
---

Notes: